Agilent Technologies to acquire Biocare Medical in $950m deal

Core Insights - Agilent Technologies has agreed to acquire Biocare Medical for $950 million, enhancing its pathology solutions portfolio [1] - The acquisition is expected to strengthen Agilent's global operations and expand its in vitro diagnostic (IVD) antibody development capabilities [2] - The transaction is anticipated to close by the fourth quarter of Agilent's 2026 fiscal year and will be accretive to earnings per share approximately 12 months post-close [3] Company Strategy - Agilent's CEO emphasized that the acquisition aligns with the company's strategy of driving long-term growth through customer-centric innovation and disciplined capital allocation [4] - The integration of Biocare is expected to enhance Agilent's ability to serve pathology customers in both clinical and research settings [4] Financial Performance - Biocare has shown consecutive double-digit growth since 2021, generating $90 million in revenue in 2025 [5] - Agilent's Life Sciences and Diagnostics Markets Group (LDG) reported revenue of $679 million in Q1 of fiscal year 2026, reflecting a 5% year-over-year growth [3]